Zobrazeno 1 - 10
of 272
pro vyhledávání: '"H. A. van Oers"'
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-11 (2018)
Abstract Background Identification of children at risk for psychosocial problems is important to be able to provide supportive and tailored care at an early stage. Due to its brevity and wide age range, the Strengths and Difficulties Questionnaire (S
Externí odkaz:
https://doaj.org/article/dd61dbd5b2014e5eac82fba10c66ff5b
Autor:
S. A. Schepers, H. A. van Oers, H. Maurice-Stam, J. Huisman, C. M. Verhaak, M. A. Grootenhuis, L. Haverman
Publikováno v:
Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-8 (2017)
Abstract Background The purpose of this study is to provide Dutch normative data and to assess internal consistency and known-groups validity for the TNO AZL Preschool Children Quality of Life (TAPQOL) and the acute version of the generic Pediatric Q
Externí odkaz:
https://doaj.org/article/afb6d1d21e094acfba30368a2fc811a2
Autor:
Michael Gregor, Florian Simon, Philipp B. Staber, Anna-Maria Fink, Christof Schneider, Vesa Lindström, Matthias Ritgen, Mels Hoogendoorn, Caspar da Cunha-Bang, Tamar Tadmor, Thomas Illmer, Maria B.L. Leijs, Arnon P. Kater, Nisha De Silva, Clemens-Martin Wendtner, Can Zhang, Julia von Tresckow, Marinus H. J. van Oers, Stephan Stilgenbauer, Henrik Frederiksen, Carsten Utoft Niemann, Moritz Fürstenau, Eugen Tausch, Michael Baumann, Sandra Robrecht, Christian Bjørn Poulsen, Ann Janssens, Holger Hebart, Monika Brüggemann, Gunnar Juliusson, Karl-Anton Kreuzer, Thomas Noesslinger, Tobias Gaska, Marjolein van der Klift, Christian H. Geisler, Kourosh Lotfi, Ilse Christiansen, Barbara Eichhorst, Björn Schöttker, Harry R. Koene, Mark-David Levin, Patrick Thornton, Michael Hallek, Kirsten Fischer, Ulrich Jaeger
Publikováno v:
Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Thomas Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U J, Frederiksen, H, B.L. Leijs, M, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Clemens-Martin Wendtner, Kreuzer, K-A, Ritgen, M, Brüggemann, M B, Tausch, E, Levin, M-D, van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Supplement 1, pp. 71 . https://doi.org/10.1182/blood-2021-146161
Eichhorst, B, Niemann, C, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, Da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U, Frederiksen, H, Leijs, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Wendtner, C-M, Kreuzer, K-A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, Van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Suppl. 1, 71 . https://doi.org/10.1182/blood-2021-146161
Eichhorst, B, Niemann, C, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, Da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U, Frederiksen, H, Leijs, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Wendtner, C-M, Kreuzer, K-A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, Van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Suppl. 1, 71 . https://doi.org/10.1182/blood-2021-146161
Background: For fit CLL patients (pts), continuous BTK inhibitor treatment is replacing CIT as standard of care in frontline setting, particularly in pts with unfavorable prognostic factors. The time limited combinations venetoclax plus obinutuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46700f17dedbd3070657cd5923f53a3a
https://portal.findresearcher.sdu.dk/da/publications/fca2ae81-daf7-4cd6-8e83-f4a2a71437b8
https://portal.findresearcher.sdu.dk/da/publications/fca2ae81-daf7-4cd6-8e83-f4a2a71437b8
Publikováno v:
Bone marrow transplantation, 56(8), 2038-2039. Nature Publishing Group
Bone Marrow Transplantation, 56(8), 2038-2039. Nature Publishing Group
Bone Marrow Transplantation, 56(8), 2038-2039. Nature Publishing Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19d24acddaa0a517ac566083f0232564
https://pure.amc.nl/en/publications/professor-anton-hagenbeek-19482021-father-of-mrd-and-lymphoma-expert(7c89d064-0eeb-467f-b751-df71d73fa7fc).html
https://pure.amc.nl/en/publications/professor-anton-hagenbeek-19482021-father-of-mrd-and-lymphoma-expert(7c89d064-0eeb-467f-b751-df71d73fa7fc).html
Autor:
M. H. M. Van Oers
Publikováno v:
MAB, Vol 74, Iss 11, Pp 529-532 (2000)
In de column van het vorige MAB-nummer schet-ste professor Rijkers drie onderwerpen uit het Ondernemerspakket 2001 dat per 1 januari 2001 kracht van wet moet krijgen. Het ging om het ver-vallen van de commerciële herwaardering, de geruisloze terugke
Externí odkaz:
https://doaj.org/article/cd27a8d3b6824d3da5baebee8093cc44
Autor:
M. H. M. Van Oers
Publikováno v:
MAB, Vol 73, Iss 5, Pp 286-289 (1999)
Externí odkaz:
https://doaj.org/article/f635a530a7374b32a559b8e508eeca41
Publikováno v:
Leukemia, 35(9), 2725-2726. Nature Publishing Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dcdf9e52d30de35639cb2acc4f29b4c
http://www.scopus.com/inward/record.url?scp=85115449624&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85115449624&partnerID=8YFLogxK
Autor:
Harry R. Koene, Lina van der Straten, J. Martijn Kerst, Sabina Kersting, Arnon P. Kater, Reinier Raymakers, Fatemeh Saberi Hosnijeh, Anton W. Langerak, Mark-David Levin, Mar Bellido, Martijn R. Schaafsma, G. Doreen te Raa, Martine E.D. Chamuleau, Jeanette K. Doorduijn, Marinus H. J. van Oers, Mels Hoogendoorn, Erik W.A. Marijt, Ward Posthuma, Sanne H. Tonino, Fransien de Boer, Michel van Gelder, Johan A. Dobber
Publikováno v:
Experimental Hematology, 89, 55. Elsevier
Experimental hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60. ELSEVIER SCIENCE INC
Experimental Hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60.e6. ELSEVIER SCIENCE INC
Saberi Hosnijeh, F, van der Straten, L, Kater, A P, van Oers, M H J, Posthuma, W F M, Chamuleau, M E D, Bellido, M, Doorduijn, J K, van Gelder, M, Hoogendoorn, M, de Boer, F, te Raa, G D, Kerst, J M, Marijt, E W A, Raymakers, R A P, Koene, H R, Schaafsma, M R, Dobber, J A, Tonino, S H, Kersting, S S, Langerak, A W & Levin, M-D 2020, ' Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study ', Experimental Hematology, vol. 89, pp. 55-60.e6 . https://doi.org/10.1016/j.exphem.2020.08.002
Experimental hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60. ELSEVIER SCIENCE INC
Experimental Hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60.e6. ELSEVIER SCIENCE INC
Saberi Hosnijeh, F, van der Straten, L, Kater, A P, van Oers, M H J, Posthuma, W F M, Chamuleau, M E D, Bellido, M, Doorduijn, J K, van Gelder, M, Hoogendoorn, M, de Boer, F, te Raa, G D, Kerst, J M, Marijt, E W A, Raymakers, R A P, Koene, H R, Schaafsma, M R, Dobber, J A, Tonino, S H, Kersting, S S, Langerak, A W & Levin, M-D 2020, ' Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study ', Experimental Hematology, vol. 89, pp. 55-60.e6 . https://doi.org/10.1016/j.exphem.2020.08.002
Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of kno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d604aeae92f4f9b8acb5fd120f55dba
https://dspace.library.uu.nl/handle/1874/408766
https://dspace.library.uu.nl/handle/1874/408766
Autor:
Eugen Tausch, Mark-David Levin, Barbara Eichhorst, Tamar Tadmor, Sandra Robrecht, Thomas Illmer, Michael Hallek, Nisha De Silva, Monika Brüggemann, Clemens-Martin Wendtner, Moritz Fürstenau, Julia Von Tresckow, Stephan Stilgenbauer, Caspar da Cunha-Bang, Björn Schöttker, Arnon P. Kater, Christof Schneider, Michael Gregor, Philipp B. Staber, Florian Simon, Anna-Maria Fink, Michael Baumann, Ilse Christiansen, Can Zhang, Kirsten Fischer, Christian Bjørn Poulsen, Carsten Utoft Niemann, Patrick Thornton, Ann Janssens, Matthias Ritgen, Marinus H. J. van Oers, Thomas Noesslinger, Christian H. Geisler
Publikováno v:
Blood. 138:2639-2639
Background: In early studies of venetoclax (ven) in CLL, severe tumor lysis syndromes (TLS) were observed leading to the implementation of multiple safety measures including a 5-week ramp up schedule. Since then, studies have consistently reported lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::459d71f49bcf7b0907ab810ddf6449c6
https://doi.org/10.1182/blood-2021-147790
https://doi.org/10.1182/blood-2021-147790
Autor:
Eugen Tausch, Barbara Eichhorst, Sandra Robrecht, Marinus H. J. van Oers, Nisha De Silva, Carsten Utoft Niemann, Monika Brüggemann, Patrick Thornton, Julia Von Tresckow, Arnon P. Kater, Caspar da Cunha-Bang, Philipp B. Staber, Anna-Maria Fink, Stephan Stilgenbauer, Can Zhang, Florian Simon, Christian H. Geisler, Matthias Ritgen, Michael Gregor, Kirsten Fischer, Mark-David Levin, Moritz Fürstenau, Michael Hallek, Anke Schilhabel, Clemens-Martin Wendtner, Tamar Tadmor
Publikováno v:
Blood. 138:72-72
Background: Venetoclax (ven)-based time-limited combination treatments have yielded high rates of undetectable MRD (uMRD) in patients (pts) with CLL. In correlative analyses, attainment of uMRD status was associated with longer progression-free survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1df87bd5448beed7020355f34be62282
https://doi.org/10.1182/blood-2021-147729
https://doi.org/10.1182/blood-2021-147729